ALK resistance from MATCH-R trial presented by Gonzalo Recondo at #MAP2018. Benjamin Besse Laura Mezquita d.planchard soria

MET TKI acquired resistance by Robin Guo #ASCO19

NSCLC TKIs by C Lovly #ASCO19

#ASCO19

Lorlatinib resistance in NSCLC patients: not only compound mutations clincancerres.aacrjournals.org/content/early/… Clinical Cancer Research Gonzalo Recondo soria Laura Mezquita Ken Olaussen

Prof. Jean-Charles Soria appointed General Director of Gustave Roussy by the french Minister of Solidarity and Health @AgnesBuzyn, for a term of 5 years. Read more ▶️ gustaveroussy.fr/en/professor-j… soria

Understanding acquired resistance to targeted therapies and #immunotherapy is crucial for #cancer patients. On purpose biopsies for genomic analysis and PDX establishment are feasible, over 330 patients participated in that approach Gustave Roussy nature.com/articles/s4169…

In Poster #1468, we show that NUV-655 is a potent, selective, and brain-penetrant ALK inhibitor by in vitro and in vivo studies. The molecule is also active against a multitude of ALK mutations known to confer resistance in NSCLC, including G1202R+. bit.ly/3uEwClz

🔬 [#Recherche] Déjouer la résistance thérapeutique au #cancer ! Les thérapies ciblées utilisent des molécules agissant spécifiquement sur les cellules cancéreuses🦠 Luc Friboulet - chercheur 👨‍🔬 au lab. PMNCO – Université Paris-Saclay Gustave Roussy Inserm 👉bit.ly/34Vl5nf

The pleasure of finally being able to meet for a drink with part of this superb team Centre International des Cancers Thoraciques dedicated to thoracic oncology, it feels good! Fabrice Barlesi soria Benjamin Besse Pamela Abdayem Friboulet Luc Hôpital Marie-Lannelongue, GHPSJ @GHPSJ Gustave Roussy

De l’or plein les yeux pour les enfants hospitalisés de Gustave Roussy grâce à la Patrouille de France, marraine d’Imagine for Margo 🤩 Mille mercis à la #PatrouilleDeFrance pour ce moment exceptionnel offert aux enfants et aux soignants de Gustave Roussy ❤️ #SeptembreEnOr

Single cell NGS of samples from patients with EGFR-mutated NSCLC after resistance to Osimertinib could identify driver alterations co-occuring in the same cancer cell, including targetable alterations annalsofoncology.org/article/S0923-… #LCSM Friboulet Luc Benjamin Besse Gustave Roussy

#AACR22 Thanks leading #ALK investigator Dr. Friboulet Luc for your collaboration on the expansive preclinical investigation of NVL-655 in support of broad clinical utility in #ALKpositive #NSCLC and other solid tumors! Poster: bit.ly/37H3R1s PR: bit.ly/3LYsKo9

Come and discuss about Lorlatinib drug tolerant in vitro phenotype and combination strategies. Floriane Brayé. Poster section 15 #20 #AACR23 Gustave Roussy

A highlights of every AACR annual meeting is the update on #KRAS biology from ⁦Channing Der⁩. Amazing how much discovery there is left after 40 years, exemplified by the new KRAS signature and thousands of new ERK phospho substrates he described. #AACR23 #KillKRAS

Come and discuss about PI3K and PTEN impact on TKI resistance. Giorgia Guaitoli. Poster section 44 #28 #AACR23 Gustave Roussy

Resistance to FGFR TKIs in urothelial carcinoma by Francesco Facchinetti Gustave Roussy #AACR23

Come to see our 148 PDX collection resistant to innovative treatments. Ludovic Bigot. Gustave Roussy #AACR23

📚We're pleased to announce our new manuscript published in Cancer Discovery characterizing NVL-655 and detailing our approach to targeting #ALK. Thank you to our preclinical and clinical collaborators! investors.nuvalent.com/2024-09-13-Nuv…